Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents comparison of linear and macrocyclic agents

Investigative Radiology

Volumn 51, Issue 2, 2016, Pages 83-89

  Jost, Gregor ^a   Lenhard, Diana Constanze ^b   Sieber, Martin Andrew ^a   Lohrke, Jessica ^a   Frenzel, Thomas ^a   Pietsch, Hubertus ^a  

^a BAYER PHARMA AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Animal experiment; Cerebrospinal fluid; Contrast agent; Gadolinium; GBCA; MRI; Pons; Retention

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; SODIUM CHLORIDE; GADOLINIUM; MACROCYCLIC COMPOUND;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBELLUM NUCLEUS; CEREBROSPINAL FLUID; CISTERNOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GLOBUS PALLIDUS; IMAGE ANALYSIS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; ANATOMY AND HISTOLOGY; ANIMAL; BRAIN; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG ADMINISTRATION; IMAGE ENHANCEMENT; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; WISTAR RAT;

ANIMALS; BRAIN; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GADOLINIUM; IMAGE ENHANCEMENT; MACROCYCLIC COMPOUNDS; MALE; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84953639577     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000242     Document Type: Article

References (29)

1. Matsumura T, Hayakawa M, Shimada F, et al. Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci. 2013;12:297-304.
2. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99:2293-2352.
3. Port M, Idée JM, Medina C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-490.
4. Idée JM, Port M, Robic C, et al. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30:1249-1258.
5. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
6. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agentsin human serum at 37 degrees C.Invest Radiol. 2008;43:817-828.
7. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidusonunenhanced T1-weightedMRimages: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834-841.
8. Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685-690.
9. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772-782.
10. Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470-472.
11. Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015;275:783-791.
12. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275:803-809.
13. Adin ME, Kleinberg L, Vaidya D, et al. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol. 2015;36:1859-1865.
14. Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015;50:743-748.
15. Robert P, Lehericy S, Grand S, et al. T1-weighted hypersignal in the deep cerebel-lar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats: difference between linear and macrocyclic agents. Invest Radiol. 2015;50:473-480.
16. Radbruch A, Weberling LD, Kieslich PJ, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced t1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50: 805-810.
17. Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobu-trol. Eur Radiol. 2015. [Epub ahead of print].
18. Agris J, Pietsch H, Balzer T. What evidence is there that gadobutrol causes increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W MRI in patients with RRMS? Eur Radiol. 2015. [Epub ahead of print].
19. Stojanov DA. Reply to letter to the editor re: increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2015. [Epub ahead of print].
20. Naganawa S, Yamazaki M, Kawai H, et al. Contrast enhancement of the anterior eye segment and subarachnoid space: detection in the normal state by heavily T2-weighted 3D FLAIR. Magn Reson Med Sci. 2011;10:193-199.
21. U.S. Department of Health and Human Devices FaDA, Center for Drug Evaluation and Research 2005. Available at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm078932.pdf.
22. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. New York: Academic Press; 2006.
23. Takahashi M, Tsutsui H, Murayama C, et al. Neurotoxicityof gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier. Magn Reson Imaging. 1996;14:619-623.
24. Lorusso V, Arbughi T, Tirone P, et al. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr. 1999;23(suppl 1):S181-S194.
25. Pietsch H, Lengsfeld P, Jost G, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009;19:1417-1424.
26. Naganawa S, Kawai H, Sone M, et al. Increased sensitivity to low concentration gadolinium contrast byoptimized heavily T2-weighted 3D-FLAIRtovisualize en-dolymphatic space. Magn Reson Med Sci. 2010;9:73-80.
27. Naganawa S, Nakashima T. Visualization of endolymphatic hydrops withMR imaging in patients with Ménière's disease and related pathologies: current status of its methods and clinical significance. Jpn J Radiol. 2014;32:191-204.
28. Naganawa S, Suzuki K, Yamazaki M, et al. Serial scans in healthy volunteers following intravenous administration of gadoteridol: time course of contrast enhancement in various cranial fluid spaces. Magn Reson Med Sci. 2014;13:7-13.
29. Brinker T, Stopa E, Morrison J, et al. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS. 2014;11:10.